March 16 | 2024
2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS
Read more
January 4 | 2024
2cureX announces changes to the Board of Directors.
Read more
December 6 | 2023
2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial
Read more
November 10 | 2023
IndiTreat® Image Uploader gets IVD CE-Mark
Read more
October 30 | 2023
2cureX participated in “Knæk Cancer” panel discussion.
Read more
October 26 | 2023
Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation
Read more
October 3 | 2023
2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).
Read more
July 5 | 2023
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)
Read more
May 11 | 2023
Positive IndiTreat® trial results published in highly recognized scientific journal.
Read more
April 25 | 2023
2cureX’s CEO Fernando Andreu purchases shares in the company
Read more
April 12 | 2023
2cureX presents preliminary Q1 2023 commercial results.
Read more
April 12 | 2023
2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.
Read more
April 10 | 2023
Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)
Read more
April 6 | 2023
2cureX strengthens its IndiTreat® automation project with a prestigious grant from the German Federal Ministry of Education and Research
Read more
March 23 | 2023
2cureX announces launch of updated Specimen Collection Set
Read more
February 15 | 2023
Invitation to 2cureX webcast on Year-End Report and latest news on February 24, 2023
Read more
January 19 | 2023
2cureX announces final results regarding 2022 goals
Read more
December 20 | 2022
2cureX reaches 2022 geographic rollout goal of 20 countries
Read more